All > Ovarian Cancer > California

Maveropepimut-S for Platinum-resistant Epithelial Ovarian Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Platinum-resistant Epithelial Ovarian CancerMaveropepimut-S - Other
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

This trial is testing a new drug, maveropepimut-S, to see if it is effective and safe in treating ovarian cancer that has come back and is resistant to platinum-based drugs.

Eligible Conditions
  • Platinum-resistant Epithelial Ovarian Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Simvastatin 40mg
1
CAR.B7-H3
1
Chimeric Antigen Receptor T-cells

Study Objectives

0 Primary · 9 Secondary · Reporting Duration: up to 23 months

at 6 months
Progression Free Survival (6m PFS)
up to 13 months
CA-125 Response
Cell mediated immune response
Disease Control Rate (DCR)
Frequency of adverse events
Objective Response Rate (ORR)
up to 2 months
Changes in Tumor Micro-environment (TME)
up to 23 months
Duration of Response (DOR)
Overall Survival (OS)
Progression Free Survival (PFS)
Time to Progression (TTP)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Simvastatin 40mg
1
CAR.B7-H3
1
Chimeric Antigen Receptor T-cells

Trial Design

1 Treatment Group

MVP-S + CPA
1 of 1

Experimental Treatment

73 Total Participants · 1 Treatment Group

Primary Treatment: Maveropepimut-S · No Placebo Group · Phase 2

MVP-S + CPAExperimental Group · 2 Interventions: Cyclophosphamide 50mg, Maveropepimut-S · Intervention Types: Drug, Other
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cyclophosphamide 50mg
2006
Completed Phase 2
~140

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 23 months

Who is running the clinical trial?

ImmunoVaccine Technologies, Inc. (IMV Inc.)Lead Sponsor
10 Previous Clinical Trials
561 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Female Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You must be expected to live for at least 6 months.
You have received ≤ 4 prior lines of anti-cancer therapy for ovarian cancer, including at least one platinum-based therapy.
You have measurable disease with at least one non-target lesion accessible by image-guided biopsy
You are willing to undergo on-treatment tumor biopsy.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top